---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268935"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:51:36.921926+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine completes EPP trial enrollment; bitopertin shows PPIX reduction and light tolerance gains

## Summary
- Enrollment complete for Phase 2 BEACON (n=22 adults) and AURORA (n=75 adults) bitopertin trials in EPP; BEACON expanded to adolescents.
- Interim BEACON data: mean PPIX reduction of 39% by Day 43; patients with >30% PPIX reduction averaged >10 hours weekly sunlight tolerance improvement.
- Proportion of prodrome-free sunlight challenges rose from 2% to 49%; phototoxic reactions decreased 93% on bitopertin.
- Initial DISC-0974 data in MF with anemia shows dose-dependent hepcidin reductions and serum iron increases; no serious AEs reported.
- Updated BEACON data and preliminary DISC-0974 results to be presented at ASH Dec 11; conference call same day at 9:30 PM ET.

## SEC filing metadata
- accession: 0001193125-23-268935
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523268935/0001193125-23-268935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523268935/d569217d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268935
- JSON: https://secwatch.observer/filing/0001193125-23-268935.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.